Stifel Financial’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$243K Buy
5,294
+111
+2% +$6.05K ﹤0.01% 3423
2026
Q2
$263K Sell
5,183
-2,741
-35% -$116K ﹤0.01% 3354
2026
Q1
$311K Buy
+7,924
New +$220K ﹤0.01% 3162

Other funds holding ELVN

Stifel Financial's ELVN Position: Q3 2026 in Review

Stifel Financial increased its Enliven Therapeutics (ELVN) stake by 2.1% in Q3 2026, buying an estimated $6.05K and bringing the position to 5,294 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #3423.

Stifel Financial first reported a position in ELVN in Q1 2026 and has held it in 3 quarters since. The position peaked at $311K in Q1 2026. 216 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Stifel Financial held 5,294 shares of Enliven Therapeutics worth $243K as of Q3 2026.
  • Stifel Financial bought 111 Enliven Therapeutics shares in Q3 2026, an estimated $6.05K.
  • Enliven Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q3 2026, its #3423 holding.
  • Stifel Financial first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Stifel Financial's Enliven Therapeutics position peaked at $311K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Stifel Financial's 13F filing for Q3 2026, filed 12 Nov 2026.